3.215

0.00% 0.005

Anavex Life Sciences Corp (AVXL)

Overview News Price History Option Chain Financials Why AVXL Down? Discussions Forecast Stock Split

Anavex Life Sciences Corp stock is traded at $3.215, with a volume of 320.12K. It is up +0.00% in the last 24 hours and up +34.73% over the past month. Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Previous Close:

$3.22

Open:

$3.19

24h Volume:

320.12K

Relative Volume:

0.27

Market Cap:

$298.02M

Revenue:

Net Income/Loss:

$-39.95M

P/E Ratio:

-6.9155

EPS:

-0.4649

Net Cash Flow:

$-34.08M

1W Performance:

-5.01%

1M Performance:

+34.73%

6M Performance:

-20.30%

1Y Performance:

-67.62%

1-Day Range:

$3.152

$3.22

1-Week Range:

$3.14

$3.57

52-Week Range:

$2.255

$10.40

Anavex Life Sciences Corp Stock (AVXL) Company Profile

Name

Anavex Life Sciences Corp

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

844-689-3939

Address

630 5TH AVENUE, NEW YORK

Employee

Twitter

@anavexlifesci

Next Earnings Date

2026-08-18

Latest SEC Filings

AVXL's Discussions on Twitter

Compare AVXL vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVXL Anavex Life Sciences Corp	3.215	298.48M	0	-39.95M	-34.08M	-0.4649
VRTX Vertex Pharmaceuticals Inc	515.76	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.65	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.87	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.83	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.63	39.31B	5.76B	514.49M	1.10B	4.4813

Anavex Life Sciences Corp Stock (AVXL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-23-22	Initiated	Berenberg	Buy
Sep-23-21	Initiated	BTIG Research	Buy
Dec-16-20	Reiterated	H.C. Wainwright	Buy
Sep-28-20	Initiated	Ladenburg Thalmann	Buy
Feb-27-20	Initiated	Cantor Fitzgerald	Overweight
Jun-18-19	Initiated	Janney	Buy
May-16-18	Resumed	Maxim Group	Buy
Mar-08-18	Initiated	ROTH Capital	Buy
Feb-13-18	Reiterated	Maxim Group	Buy
Sep-29-17	Resumed	Noble Financial	Buy
Feb-07-17	Initiated	Noble Financial	Buy
Mar-29-16	Initiated	FBR Capital	Outperform

View All

Anavex Life Sciences Corp Stock (AVXL) Latest News

08:26 AM

Form 8K Anavex Life Sciences Corp For: 17 August By Investing.com - Investing.com India

08:26 AM

08:17 AM

Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees - The Manila Times

08:17 AM

08:00 AM

Six Anavex Director Nominees Face a Sept. 24 Vote—What Sets Them Apart? - Stock Titan

08:00 AM

Aug 15, 2026

Promising Penny Stocks To Consider In August 2026 - Sahm

Aug 15, 2026

(AVXL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Aug 15, 2026

Aug 14, 2026